Zobrazeno 1 - 4
of 4
pro vyhledávání: '"D. A. Chaginskaya"'
Autor:
V. G. Potapenko, N. B. Mikhaylova, B. I. Smirnov, I. A. Skorokhod, D. A. Chaginskaya, V. V. Ryabchikova, I. А. Samorodova, E. I. Podol’tseva, V. V. Ipatov, I. V. Boykov, V. N. Semelev, D. A. Gornostaev, T. G. Potapenko, T. G. Kulibaba, N. V. Medvedeva, B. V. Afanas’ev
Publikováno v:
Онкогематология, Vol 11, Iss 4, Pp 18-24 (2017)
Objective: evaluation and comparison of positron emission tomography (PET) prognostic value with other predictors of effectiveness in patients with non-Hodgkin’s lymphoma (NHL) receiving high-dose chemotherapy with autologous hematopoietic stem cel
Externí odkaz:
https://doaj.org/article/212c5c792aac40e695e2d4b29e9c47a2
Autor:
V. G. Potapenko, E. V. Baumert, A. A. Bobrova, R. V. Vashchenkov, N. V. Dorofeeva, K. D. Kaplanov, E. V. Karyagina, A. N. Levanov, A. S. Luchinin, S. I. Moiseev, A. V. Novitskii, A. S. Nizamutdinova, О. V. Pirogova, S. A. Povzun, М. V. Platonov, V. V. Porunova, D. А. Ptashnikov, V. V. Ryabchikova, S. Ya. Simeniv, I. А. Skorokhod, Е. А. Ukrainchenko, D. А. Chaginskaya, T. V. Shelekhova, M. N. Shirokova, A. A. Shutylev, N. V. Medvedeva
Publikováno v:
Oncohematology. 17:48-61
Background. The treatment options for patients with multiple myeloma who refractory to previous bortezomib and lenalidomide therapy are limited. Pomalidomide is ап immunomodulatory agent that was registered for the treatment of patients with double
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bedf905aad127a83eea7f46a4ada09ce
https://doi.org/10.17650/1818-8346-2022-17-3-48-61
https://doi.org/10.17650/1818-8346-2022-17-3-48-61
Autor:
N. V. Medvedeva, B. I. Smirnov, D. A. Chaginskaya, V. N. Semelev, V. G. Potapenko, T. G. Kulibaba, N. B. Mikhaylova, V. V. Ipatov, I. А. Samorodova, E. I. Podol’tseva, DA , , Gornostaev, T. G. Potapenko, V. V. Ryabchikova, I. A. Skorokhod, I. V. Boykov, B. V. Afanas’ev
Publikováno v:
Onkogematologiâ, Vol 11, Iss 4, Pp 18-24 (2017)
Objective: evaluation and comparison of positron emission tomography (PET) prognostic value with other predictors of effectiveness in patients with non-Hodgkin’s lymphoma (NHL) receiving high-dose chemotherapy with autologous hematopoietic stem cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f9239ea490ce8cca4890d721106121f
https://oncohematology.abvpress.ru/ongm/article/view/212
https://oncohematology.abvpress.ru/ongm/article/view/212
Autor:
IA Samorodova, V. N. Semelev, VG Potapenko, V. V. Ipatov, V. V. Ryabchikova, BV Afanas’ev, I. A. Skorokhod, DA , , Gornostaev, T.G. Kulibaba, EI Podol’tseva, T. G. Potapenko, IV Boikov, B. I. Smirnov, D. A. Chaginskaya, N. V. Medvedeva, NB Mikhailova
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 9, Iss 4, Pp 406-412 (2016)
Aim. To perform a comparative analysis of the prognostic significance of positron-emission tomography (PET) with other prognostic factors of the efficacy of high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (auto-H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64c7dc85d2c4a1315cd9bd60149adc05
http://bloodjournal.ru/en/role-of-positron-emission-tomography-in-prognosis-of-outcomes-of-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-transplantation-in-hodgkin-s-lymphoma-2/
http://bloodjournal.ru/en/role-of-positron-emission-tomography-in-prognosis-of-outcomes-of-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-transplantation-in-hodgkin-s-lymphoma-2/